<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01376752</url>
  </required_header>
  <id_info>
    <org_study_id>FEDEGYN 02 / 0410-CHIPOR</org_study_id>
    <secondary_id>2010-023035-42</secondary_id>
    <nct_id>NCT01376752</nct_id>
  </id_info>
  <brief_title>Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) in Relapse Ovarian Cancer Treatment</brief_title>
  <acronym>CHIPOR</acronym>
  <official_title>A Phase III Randomized Study Evaluating Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) in the Treatment of Relapse Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UNICANCER</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      CHIPOR hypothesis is that the adjunction of platinum HIPEC in first relapsed epithelial
      ovarian cancer is able to improve the median Overall Survival (OS) by 12 months. In that
      hypothesis, with alpha risk of 5%, a power beta of 80%, during a 3 years period of inclusion
      and a 3 years follow-up, the number of patients to include is 404. Taking into account a 10%
      failure, an overall number of 444 patients is required.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The patient received before the surgery a second line chemotherapy, platinum-based regimen
      with either carboplatine-paclitaxel, or carboplatine-caelyx. At the end of the six courses IV
      chemotherapy, if the disease is still responding and if a complete cytoreductive surgery
      seems possible, the patient is included after signed informed consent and will be operated 5
      to 8 weeks after the last second-line chemotherapy cycle.

      So, during the surgery the patient will be randomized if the complete cytoreductive surgery
      is really done and will then receive:

        -  either treatment A = maximal cytoreductive surgery without HIPEC

        -  or treatment B = maximal cytoreductive surgery with HIPEC

      The HIPEC will be done at the end of the surgery. At the end of cytoreductive surgery, tumor
      residual disease must be null or very limited (Sugarbaker completeness cytoreduction: CC0 (no
      residual)-CC1 (residual &lt; 0.25cm).

      Two methods will be used for the HIPEC: Open or closed abdomen, depends on the site practice.
      Each site will use the same method during the study for all included patients.
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Temporary suspension since March 20th 2020 due to COVID-19 pandemic
  </why_stopped>
  <start_date type="Actual">April 2011</start_date>
  <completion_date type="Anticipated">April 2025</completion_date>
  <primary_completion_date type="Anticipated">September 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>from randomization to death (up to 4 years)</time_frame>
    <description>Follow-up of 4 years.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>relapse free survival</measure>
    <time_frame>from randomization to relapse (up to 4 years)</time_frame>
    <description>Follow-up of 4 years.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">444</enrollment>
  <condition>Ovarian Epithelial Cancer Recurrent</condition>
  <arm_group>
    <arm_group_label>maximal cytoreductive surgery without HIPEC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The participant will have a regular cytoreductive surgery without the adjunction of HIPEC.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>maximal cytoreductive surgery with HIPEC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The participant will have a regular cytoreductive surgery, then the adjunction of HIPEC: hyperthermic cisplatin will be used at 75mg/m²</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Maximal cytoreductive surgery</intervention_name>
    <description>Maximal cytoreductive surgery</description>
    <arm_group_label>maximal cytoreductive surgery with HIPEC</arm_group_label>
    <arm_group_label>maximal cytoreductive surgery without HIPEC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HIPEC</intervention_name>
    <description>HIPEC: Hyperthermic Intra-PEritoneal Chemotherapy. Administration of cisplatin at 75mg/m²</description>
    <arm_group_label>maximal cytoreductive surgery with HIPEC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient age ≥ 18 years

          -  Performance Status WHO &lt; 2

          -  Initially treated for Epithelial Ovarian Carcinoma

          -  Patient with only peritoneal relapse occurred at least 6 month from the initial
             treatment, resectable without distant metastasis (with the exception of communicating
             pleura effusion, sensitive to platine-based second line chemotherapy and resectable
             lymph-nodes in the groin or retro peritoneal)

          -  Platinum based second-line chemotherapy before surgery with either
             carboplatine-paclitaxel, or carboplatine-caelyx

          -  Complete cytoreductive surgery

          -  The surgery has to be planned 5 to 8 weeks from the last 2nd of chemotherapy

          -  No hepatic failure, bilirubin ≤ 1,5 time the Normal limit, ASAT and ALAT ≤ 3 time the
             Upper Normal Limit

          -  No Renal insufficiency (serum creatinine &lt; 1,5 time the normal limit, creatinine
             clearance &gt; 80 mL/min). calculated with MDRD method

          -  Hematology function: PNN ≥ 1,5x10⁹/L, platelets ≥ 100x10⁹/L

          -  No contraindication to general anaesthesia for heavy surgery

          -  Patients having read, signed and dated Informed consent before any study procedure

          -  Childbearing patients have to take appropriate contraceptive methods during the
             treatment and until 6 months after the treatment

        Exclusion Criteria:

          -  Patient age &lt;18 years

          -  Previous cancer in the last 5 years (except cutaneous baso-cellular epithelioma or
             uterine peripheral epithelioma)

          -  Hypersensitivity to Platinum compound

          -  Distant metastasis

          -  Use of anti-angiogenic treatment

          -  Patient with other concurrent severe life threatening disease

          -  The need to perform more than two segmental digestive resections during the CRS +/-
             HIPEC surgery

          -  Any progressive disease during the IV systemic second-line chemotherapy
             (platine-based)

          -  Incomplete cytoreductive surgery with macroscopical residual disease (Sugarbaker &gt;
             CC1)

          -  Early relapse: less than 6 mois after the end of the first treatment

          -  Ovarian tumor other than Epithelioma Ovarian Cancer

          -  Uncontrolled infection

          -  Patients with any psychological, familial, sociological or geographical condition
             potentially hampering compliance with the study protocol and follow-up schedule

          -  Clinically significant cardiovascular disease contraindicating the hyper hydratation,
             which is necessary for HIPEC

          -  Patient already treated with HIPEC for the ovarian cancer

          -  Individual deprived of liberty or placed under the authority of a tutor
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Marc CLASSE</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre rené Gauducheau, NANTES</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU d'AMIENS</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Paul Papin</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinique Kéraudren</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Francois Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier de Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Victor Hugo</name>
      <address>
        <city>Le Mans</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pôle Santé Sud</name>
      <address>
        <city>Le Mans</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Dupuytren</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hopsitalier Lyon Sud</name>
      <address>
        <city>Lyon</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HM - Hôpital de la Timone</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRLC Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Nice</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Lariboisiere</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU - Hôpital de la Milétrie</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Saint Etienne- Hopital Nord</name>
      <address>
        <city>Saint-etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ico-Centre Rene Gauducheau</name>
      <address>
        <city>Saint-herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Alexis Vautrin</name>
      <address>
        <city>Vandoeuvre-les-nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias I Pujol</name>
      <address>
        <city>Badalona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Spain</country>
  </location_countries>
  <results_reference>
    <citation>Brigand C, Monneuse O, Mohamed F, Sayag-Beaujard AC, Isaac S, Gilly FN, Glehen O. Peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy: results of a prospective study. Ann Surg Oncol. 2006 Mar;13(3):405-12. Epub 2006 Jan 30.</citation>
    <PMID>16485159</PMID>
  </results_reference>
  <results_reference>
    <citation>Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA; Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006 Jan 5;354(1):34-43.</citation>
    <PMID>16394300</PMID>
  </results_reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 28, 2011</study_first_submitted>
  <study_first_submitted_qc>June 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2011</study_first_posted>
  <last_update_submitted>April 17, 2020</last_update_submitted>
  <last_update_submitted_qc>April 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

